

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Bingham et al.
Serial No.: 10/019,976

Docket No. PU3650USW
International Application No. :
PCT/EP00/03848
IA Filing Date: 28 April 2000

Title: IMIDAZOLINE DERIVATIVES AS
ALPHA-1A ADRENOCEPTOR LIGANDS

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS
UNDER 35 U.S.C. 371 IN THE U.S. DESIGNATED/ELECTED OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office mailed March 29, 2002, Applicant submits that the Notification was issued in error. There are no sequences contained in the specification as filed. Accordingly, the requirements for disclosure as set forth under 37 CFR 1.821-1.825 do not apply.

In consideration of the foregoing, Applicant respectfully requests that the Notification be withdrawn and a Notice of Acceptance dated 23 October 2001, the original date of filing, be issued

No fee is believed due in connection with this submission. However, if a fee is required, you are hereby authorized to charge Deposit Account No. 07-1392.

Respectfully submitted,


John L. Lemanowicz
Registration No. 37,380

Dated: 20 May 2002

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
Research Triangle Park, NC 27709
Telephone No.: (919) 483-3323
Facsimile No.: (919) 483-7988

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Bingham

Docket No.

PU3650USw

Serial No.

10/019,976

Filing Date

Examiner

Group Art Unit

Invention:

IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS

I hereby certify that this Response to Notification of Missing Requirement Under 35 U.S.C. 371
(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.

20231-0001 on 20 May 2002
(Date)

Ban Younan

(Typed or Printed Name of Person Mailing Correspondence)

Ban Younan

(Signature of Person Mailing Correspondence)

EV022026407US

Note: Each paper must have its own certificate of mailing.



UNITED STATES PATENT AND TRADEMARK OFFICE


Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/019,976	FIRST NAMED APPLICANT Eric Cleveland Bigham	ATTY. DOCKET NO. PU3650USw
---	--	-------------------------------

23347
 DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY
 GLAXOSMITHKLINE
 FIVE MOORE DR.
 PO BOX 13398
 DURHAM, NC 27709-3398

INTERNATIONAL APPLICATION NO. PCT/EP00/03848	
I.A. FILING DATE 04/28/2000	PRIORITY DATE 04/30/1999

CONFIRMATION NO. 2196
 371 FORMALITIES LETTER




OC000000007735376

Date Mailed: 03/29/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination



The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

• For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/019,976	PCT/EP00/03848	PU3650USw